The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

被引：2
|
作者：
Addeo, Raffaele [1 ]
Caraglia, Michele [2 ]
机构：
[1] S Giovanni di Dio Hosp, Oncol Unit, ASL Napoli 2, I-80027 Naples, Italy
[2] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2011年 / 11卷 / 02期
关键词：
blood-brain barrier; brain metastasis; breast cancer; chemotherapy; lapatinib; sunitinib; tyrosine kinase inhibitor; whole-brain radiotherapy; NERVOUS-SYSTEM METASTASES; PHASE-II TRIAL; TEMOZOLOMIDE; CARCINOMA; RADIOTHERAPY; CAPECITABINE; BEVACIZUMAB; COMBINATION; THERAPY; DISEASE;
D O I：
10.1586/ERA.10.190
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：139 / 142
页数：4
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
    Duchnowska, Renata
    Loibl, Sibylle
    Jassem, Jacek
    CANCER TREATMENT REVIEWS, 2018, 67 : 71 - 77
  • [2] IMPACT OF TREATMENT WITH TYROSINE KINASE INHIBITORS ON BRAIN METASTASES FROM RENAL CELL CARCINOMA
    Bassanelli, M.
    Felici, A.
    Giacinti, S.
    Baldoni, A.
    Aschelter, A. M.
    Marchetti, P.
    ANTICANCER RESEARCH, 2013, 33 (05) : 2336 - 2337
  • [3] Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib
    Ammannagari, N.
    Ahmed, S.
    Patel, A.
    Bravin, E. N.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2013, 106 (09) : 869 - 870
  • [4] KGFR Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
    Pento, T.
    Meghna, M. M.
    Kesinger, J. W.
    Brueggemeier, R. W.
    Hackett, J.
    Xiao, Z.
    Lerner, M. R.
    Brackett, D. J.
    Awasthi, V.
    Li, P-K.
    CANCER RESEARCH, 2010, 70
  • [5] Lapatinib: new opportunities for management of breast cancer
    Liao, Julia
    Gallas, Michelle
    Pegram, Mark
    Slingerland, Joyce
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 79 - 91
  • [6] Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib
    Spraggs, C. F.
    Parham, L. R.
    Song, K.
    Briley, L. P.
    Johnson, T.
    Russo, M.
    Tada, H.
    du Bois, A.
    Xu, C. -F.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1515 - 1517
  • [7] Lapatinib treatment with Capecitabine in a patient with scattered breast cancer along with metastases in the brain
    Makarewicz, Adrianna
    Zurawski, Bogdan
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : D15 - D16
  • [8] The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma
    Verma, Jonathan
    Jonasch, Eric
    Allen, Pamela K.
    Weinberg, Jeffrey S.
    Tannir, Nizar
    Chang, Eric L.
    Mahajan, Anita
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (06): : 620 - 624
  • [9] EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
    Bartolotti, Marco
    Franceschi, Enrico
    Brandes, Alba Ariela
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1429 - 1435
  • [10] Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer
    Sardesai, Sagar D.
    Storniolo, Anna Maria
    WOMENS HEALTH, 2015, 11 (03) : 281 - 294
12345